• Encompass Health reported past fourth-quarter 2025 results that topped Wall Street expectations and issued 2026 guidance for net operating revenue of about US$6.37 billion to US$6.47 billion and earnings of US$5.81 to US$6.10 per share.
• The company also added veteran health plan executive Cain A. Hayes to its board, deepening its expertise in healthcare payor operations, regulation, and risk management at a time when reimbursement and cost pressures remain central to its inpatient rehabilitation business model.
• We’ll now examine how this earnings beat and above-consensus full-year guidance shape Encompass Health’s investment narrative for long-term investors.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Encompass Health's Investment Narrative?

To own Encompass Health, you have to believe in a disciplined, hospital-based rehabilitation business that can keep growing earnings without outsized revenue expansion, despite high leverage and reimbursement uncertainty. The latest quarter’s earnings beat and new 2026 guidance, which roughly align with prior analyst expectations, mostly reinforce rather than redefine that story: the near-term catalysts still center on execution at new hospitals, maintaining healthy margins, and proving that returns justify the recent build-out in capacity. The stock’s rebound after results suggests the beat and above-consensus EPS guidance mattered for sentiment, but they probably do not erase the key risk that tighter payer behavior or regulatory shifts could squeeze profitability. The addition of Cain Hayes to the board directly targets that concern, sharpening Encompass Health’s insight into health plan economics and potential reimbursement friction.

However, reimbursement pressure remains a key issue investors should be watching closely.
Encompass Health's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four Simply Wall St Community fair value views span roughly US$99 to a very large US$378, underlining how far apart individual expectations can sit. Set that against the current focus on payer risk and margin resilience, and you may want to weigh which side of that spectrum better fits your view of how those pressures play out for Encompass Health.

Explore 4 other fair value estimates on Encompass Health - why the stock might be worth over 3x more than the current price!

Build Your Own Encompass Health Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Encompass Health research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 30 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.